We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA Eyes Heart Risks Of Proposed Lundbeck Drug

Law360 (April 3, 2009, 12:00 AM EDT) -- Officials at the U.S. Food and Drug Administration have expressed concern about a risk of cardiac arrhythmia and death associated with Danish drugmaker H. Lundbeck A/S's proposed schizophrenia drug Serdolect....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.